Caladrius acquires license to CD34+ cell therapy program from Shire

This article was originally published here

Caladrius Biosciences has acquired an exclusive worldwide license to data from Shire’s late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply